FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer.

Johannes BreyerRalph M WirtzPhilipp ErbenSebastien RinaldettiThomas S WorstRobert StoehrMarkus EcksteinDanijel SikicStefan DenzingerMaximilian BurgerArndt HartmannWolfgang Otto

Published in: BJU international (2018)

High FOXM1 expression was associated with adverse clinical and pathological features and worse outcomes, and predicted response to intravesical instillation therapy in patients with stage pT1 NMIBC.

Keyphrases

muscle invasive bladder cancer
poor prognosis
emergency department
stem cells
type diabetes
adipose tissue
transcription factor
metabolic syndrome
bone marrow
skeletal muscle
mesenchymal stem cells
weight loss